Targeted enzymes
First Claim
Patent Images
1. A pharmaceutical composition comprising a targeted enzyme (TE) and a pharmaceutically acceptable carrier, excipient or diluent, said TE exhibiting a catalytic activity and comprising:
- a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme, ii) the target is bound by the TE but not by the pre-targeted enzyme under like conditions, iii) the target is not an isolated monoclonal antibody, and iv) the variation-tolerant sequence is not in a protein binding domain of the pre-targeted enzyme.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.
38 Citations
37 Claims
-
1. A pharmaceutical composition comprising a targeted enzyme (TE) and a pharmaceutically acceptable carrier, excipient or diluent, said TE exhibiting a catalytic activity and comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme, ii) the target is bound by the TE but not by the pre-targeted enzyme under like conditions, iii) the target is not an isolated monoclonal antibody, and iv) the variation-tolerant sequence is not in a protein binding domain of the pre-targeted enzyme. - View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
2. A targeted enzyme exhibiting a catalytic activity, comprising:
-
a) a substrate recognition site;
b) a first targeting site that binds a first target; and
c) a second targeting site that binds a second target, wherein i) each targeting site comprises a variant sequence derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, and ii) the affinity of the targeted enzyme for the first and second target is greater than the affinity of the pre-targeted enzyme for the first and second target under like conditions. - View Dependent Claims (3, 4, 5, 6)
-
-
7. A targeted enzyme exhibiting a catalytic activity, comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target, wherein i) the targeting site comprises two variant sequences derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, ii) the affinity of the targeted enzyme for the target is greater than the affinity of the pre-targeted enzyme for the target under like conditions, and iii) the target is not an isolated monoclonal antibody.
-
-
8. A targeted enzyme exhibiting a catalytic activity, comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises three variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, and ii) the affinity of the targeted enzyme for the target is greater than the affinity of the pre-targeted enzyme for the target under like conditions.
-
-
23. A pharmaceutical composition comprising a targeted -lactamase enzyme and a pharmaceutically acceptable carrier, excipient, or diluent, said enzyme comprising:
-
a) a substrate recognition site;
b) a targeting site that binds a target; and
c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme that does not bind the target, ii) the target is bound by the targeted β
-lactamase enzyme but not by the pre-targeted β
-lactamase enzyme under like conditions, andiii) the target is not an isolated monoclonal antibody. - View Dependent Claims (31, 32, 33, 34)
-
-
24. A targeted β
- -lactamase enzyme exhibiting a catalytic activity, comprising;
a) a substrate recognition site;
b) a first targeting site that binds a first target;
c) a second targeting site that binds a second target; and
d) a sequence KTXS at its substrate recognition site, wherein i) each targeting site comprises a variant sequence derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, and ii) the affinity of the targeted enzyme for the first and second target is greater than the affinity of the pre-targeted enzyme for the first and second target under like conditions. - View Dependent Claims (25, 26, 27, 28)
- -lactamase enzyme exhibiting a catalytic activity, comprising;
-
29. A targeted β
- -lactamase enzyme exhibiting a catalytic activity, comprising;
a) a substrate recognition site;
b) a targeting site that binds a target, and c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises three variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted β
-lactamase enzyme, andii) the affinity of the targeted β
-lactamase enzyme for the target is greater than the affinity of the pre-targeted β
-lactamase enzyme for the target under like conditions.
- -lactamase enzyme exhibiting a catalytic activity, comprising;
-
30. A targeted β
- -lactamase enzyme exhibiting a catalytic activity, comprising;
a) a substrate recognition site; and
b) a targeting site that binds a target, and c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises two variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted β
-lactamase enzyme,ii) the affinity of the targeted β
-lactamase enzyme for the target is greater than the affinity of the pre-targeted β
-lactamase enzyme for the target, andiii) the target is not an isolated monoclonal antibody.
- -lactamase enzyme exhibiting a catalytic activity, comprising;
-
35. A method of making a targeted enzyme, comprising:
-
a) generating a modified enzyme library by modifying a variation-tolerant sequence of an enzyme, wherein said enzyme comprises a substrate recognition site and has a catalytic activity, such that a multiplicity of modified enzymes is produced; and
b) selecting a first and second modified enzyme from the modified enzyme library that binds a target with an affinity that is greater than the affinity of the pre-modified enzyme for the target;
c) recombining a nucleic acid molecule that encodes the first modified enzyme and a nucleic acid that encodes the second modified enzyme so that a recombined nucleic acid molecule is formed that encodes a third modified enzyme; and
d) assaying the third modified enzyme for binding of the target with an affinity that is greater than the affinity of the pre-modified enzyme for the target under like conditions and for the catalytic activity while bound to the target. - View Dependent Claims (36)
-
-
37. A method of making a targeted enzyme, comprising:
-
a) generating a modified enzyme library by modifying a variation-tolerant sequence of an enzyme, wherein said enzyme comprises a substrate recognition site and has a catalytic activity, such that a multiplicity of modified enzymes is produced;
b) identifying a modified enzyme from the modified enzyme library that binds a target with an affinity that is greater than the affinity of the pre-modified enzyme for the target and has the catalytic activity while bound to the target, c) repeating a cycle of a) and b) as necessary to identify a modified enzyme that binds the target with an affinity that is at least 100-fold greater than the affinity of the unmodified enzyme for the target, wherein an enzyme modified in a further cycle of a) was identified in a previous cycle of b).
-
Specification